Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

• Status: Recruiting
• Trial end date: 2023-07-18
• Target enrollment: 0
• Participant gender: Female

Summary

Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Candesartan

Criteria

Inclusion Criteria:

• Female aged ≥ 18 years

• Pathologically confirmed HER2-positive breast cancer

• Adjuvant treatment plan comprises at least 12 cycles of Trastuzumab

• Baseline echocardiogram should be performed before starting trastuzumab

• Cumulative anthracycline dose ≤ 300mg/m2

• Written informed consent to participate in the study

Exclusion Criteria:

• History of hypersensitivity or alllergic reaction to the study medication

• Metastatic breast cancer

• Treatment with angiotensin converting enzyme(ACE) inhibitor , Angiotensin receptor blocker (ARB), beta-blocking agents, or diuretics

• Patients with NCI/CTCAE grade ≥ 2 congestive heart failure, myocardial infarction, symptomatic left ventricular systolic dysfunction, heart's valve disease (≥ moderate), arrhythmias (Grade ≥ 3) < 12 months before enrollment

• Pregnancy or breast feeding

• Baseline systolic pressure < 90mmHg

• Cumulative anthracycline dose > 300mg/m2

• Serious concurrent illness